James A. McNulty - 13 Dec 2022 Form 3 Insider Report for Inhibitor Therapeutics, Inc. (INTI)

Role
Chief Financial Officer, Treasurer, Secretary of the Company, 10%+ Owner
Signature
/s/ James McNulty
Issuer symbol
INTI
Transactions as of
13 Dec 2022
Net transactions value
$0
Form type
3
Filing time
22 Dec 2022, 20:31:22 UTC
Next filing
17 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding INTI Common Stock 548,000 13 Dec 2022 Direct
holding INTI Common Stock 85,627,069 13 Dec 2022 See Footnotes F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding INTI Options 13 Dec 2022 Common Stock 150,000 $0.2400 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent 6,000,000 shares of common stock held by Hopkins Capital Group II, LLC ("HCG II LLC") and 79,627,069 shares of common stock held by Hedgepath, LLC ("HP LLC").
F2 Mr. McNulty is the manager of HCG II LLC and HP LLC. As such, Mr. McNulty may be deemed to have beneficial ownership of the common stock held by HCG II LLC and HP LLC through his voting and dispositive control over HCG II LLC and HP LLC. Mr. McNulty disclaims any beneficial ownership of the reported shares held by HCG II LLC and HP LLC other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

Remarks:

Chief Financial Officer, Treasurer, Secretary of the Company